Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Immunic's cash to debt ratio for the quarter that ended in Dec. 2023 was 34.99.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Immunic could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Immunic's Cash-to-Debt or its related term are showing as below:
IMUX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 34.99 Med: 5065.29 Max: No Debt
Current: 34.99
During the past 13 years, Immunic's highest Cash to Debt Ratio was No Debt. The lowest was 34.99. And the median was 5065.29.
Immunic Cash-to-Debt Historical Data
The historical data trend for Immunic's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
|
Immunic Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
|
|
|
|
|
56.48 |
130.59 |
87.56 |
74.46 |
34.99 |
|
Immunic Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
74.46 |
48.53 |
41.01 |
41.14 |
34.99 |
Competitive Comparison
For the Biotechnology subindustry, Immunic's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunic Cash-to-Debt Distribution
For the Biotechnology industry and Healthcare sector, Immunic's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Immunic's Cash-to-Debt falls into.
Immunic Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Immunic's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Immunic's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunic (Immunic) Business Description
Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Executives
| Glenn Whaley |
officer: PAO and Controller |
C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960 |
| Richard Alan Rudick |
director |
1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036 |
| Joerg Neermann |
director |
IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152 |
| Daniel Vitt |
director, officer: CEO, President |
IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152 |
| Monika Maria Toernsen |
director |
ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103 |
| Duane Nash |
director |
C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128 |
| Andreas Muehler |
officer: Chief Medical Officer |
1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036 |
| Manfred Groeppel |
officer: Chief Operating Officer |
IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152 |
| Barclay A Phillips |
director |
C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008 |
| Tamar D Howson |
director |
|
| Sanjay S Patel |
officer: Chief Financial Officer |
10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960 |
| Claudio Nessi |
10 percent owner |
C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204 |
| Anne-mari Paster |
10 percent owner |
C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
| Omega Fund V Gp, L.p. |
10 percent owner |
888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
| Lsp V Cooperatieve U.a. |
10 percent owner |
JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV |
Immunic (Immunic) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMUX has been successfully added to your